RSVpreF Vaccine Effective in Preventing Severe RSV in Older Adults
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 18, 2024 -- Respiratory Syncytial Virus Prefusion F (RSVpreF) vaccination is effective against RSV-related lower respiratory tract disease (LRTD) among adults aged 60 years or older, according to a study published online Dec. 13 in JAMA Network Open.
Sara Y. Tartof, Ph.D., M.P.H., from Kaiser Permanente Southern California in Pasadena, and colleagues estimated RSVpreF vaccine effectiveness in older adults in a retrospective case-control study. Cases were adults aged 60 years or older (mean age, 76.8 years) with hospitalizations or emergency department visits for LRTD from Nov. 24, 2023, to April 9, 2024, who had respiratory swabs collected and tested for RSV.
The study included 7,047 LRTD-related hospitalizations or emergency department encounters with RSV testing results. Overall, 14.2 percent were immunocompromised and 93.3 percent had one or more Charlson comorbidity. The estimated adjusted vaccine effectiveness was 91 percent using a strict control definition that included RSV-negative LRTD events that were negative for human metapneumovirus, severe acute respiratory syndrome coronavirus 2, and influenza and positive for a non-vaccine-preventable cause. Estimated adjusted vaccine effectiveness was 90 percent using a broad control definition, including all RSV-negative LRTD events.
"Based on our study results and RSV incidence in older adults, for approximately every 250 persons vaccinated, one RSV-related emergency department or hospitalization encounter could be prevented in the first season after vaccination," the authors write. "These data suggest use of RSVpreF in older adults, providing an opportunity to reduce severe medically attended RSV disease burden."
Several authors disclosed ties to biopharmaceutical companies, including Pfizer, which manufactures the RSVpreF vaccine and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization
WEDNESDAY, May 28, 2025 -- Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event compared with COVID-19...
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among...
Nirsevimab Effective for Reducing Burden of RSV in Infants
THURSDAY, May 8, 2025 -- Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.